Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical, on Tuesday, June 9that 4:00 PM ETRegister here IRVINE, CA / ACCESS Newswire / June 2, 2026 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that Robert Berman, Chief Executive Officer of enVVeno Medical will participate in a Virtual Investor Closing Bell event on Tuesday, June 9, 2026 at 4:00 PM ET.As part of the event, Mr. Berman will discuss the Company's recently reported IDE approval of its enVVe® System, marking a first-ever FDA IDE approval for a U.S. pivotal study of a non-surgical replacement venous valve.Additionally, there will be a live question and answer session with audience participants. Mr. Berman will answer as many questions as possible in the time allowed.A live video webcast will be available on the Events page of the Company's website (www.envveno.com). A webcast replay will become available two hours following the live event and will be accessible for 90 days.About enVVeno Medical CorporationenVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company is currently developing the enVVe system, which includes a first-in-class non-surgical replacement venous valve being developed for the treatment of severe Deep Venous Insufficiency (DVI). The enVVe valve is designed to act as one-way valve, to help assist in propelling blood up the leg, and back to the heart and lungs. As a transcatheter delivered device, the enVVe procedure will be performed under light sedation and should not require an over-night hospital stay.INVESTOR CONTACT:JTC Team, LLCJenene ThomasNVNO@jtcir.com(908) 824-0775SOURCE: enVVeno Medical CorporationView the original press release on ACCESS Newswire
enVVeno Medical to Participate in the Virtual Investor Closing Bell Series
Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical, on Tuesday, June 9that 4:00 PM ETRegister here IRVINE, CA / ACCESS Newswire / June 2, 2026 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that Robert Berman, Chief Executive Officer of enVVeno Medical will participate in a Virtual Investor Closing Bell event on Tuesday, June 9, 2026 at 4:00 PM ET.As part of the event, Mr. Berman will discuss the Company's recently reported IDE approval of its enVVe® System, marking a first-ever FDA IDE approval for a U.S. pivotal study of a non-surgical replacement venous valve.Additionally, there will be a live question and answer session with audience participants. Mr. Berman will answer as many questions as possible in the time allowed.A live video webcast will be available on the Events page of the Company's website (www.envveno.com). A webcast replay will become available two hours following the live event and will be accessible for 90 days.About enVVeno Medical CorporationenVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company is currently developing the enVVe system, which includes a first-in-class non-surgical replacement venous valve being developed for the treatment of severe Deep Venous Insufficiency (DVI). The enVVe valve is designed to act as one-way valve, to help assist in propelling blood up the leg, and back to the heart and lungs. As a transcatheter delivered device, the enVVe procedure will be performed under light sedation and should not require an over-night hospital stay.INVESTOR CONTACT:JTC Team, LLCJenene ThomasNVNO@jtcir.com(908) 824-0775SOURCE: enVVeno Medical CorporationView the original press release on ACCESS Newswire
